Maximal Cytoreductive Surgery as a Reasonable Therapeutic Alternative for Recurrent Endometrial Carcinoma
- 1 July 1998
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 70 (1) , 90-93
- https://doi.org/10.1006/gyno.1998.5017
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Phase II Trial of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996
- Chemotherapy plus Sequential Hormonal Therapy for Advanced and Recurrent Endometrial Carcinoma: A Phase II StudyGynecologic Oncology, 1996
- Treatment of Recurrent Adenocarcinoma of the Endometrium with Pelvic ExenterationGynecologic Oncology, 1996
- Cisplatin, Adriamycin, Etoposide, Megestrol Acetate versus Melphalan, 5-Fluorouracil, Medroxyprogesterone Acetate in the Treatment of Endometrial CarcinomaGynecologic Oncology, 1995
- Surgical Stage IV Endometrial Carcinoma: A Study of 47 CasesGynecologic Oncology, 1994
- Treatment of Advanced or Recurrent Endometrial Carcinoma with Single-Agent CarboplatinGynecologic Oncology, 1993
- The justification for a surgical staging system in endometrial carcinomaRadiotherapy and Oncology, 1993
- Total pelvic exenteration with preservation of fecal continenceJournal of Surgical Oncology, 1993
- Recurrent endometrial adenocarcinoma after surgery alone: prognostic factors and treatmentRadiotherapy and Oncology, 1993
- Recurrent adenocarcinoma of the endometrium: A clinical and histopathological study of 379 patientsGynecologic Oncology, 1984